Why the study?
Does fasudil improve endothelial function in human subjects with coronary artery disease?
Population
29 human subjects (13 with coronary artery disease and 16 age- and sex-matched healthy controls)
Comparison
Rho kinase inhibitor, fasudil, for 1 month vs Placebo for 1 month
Design
RCT, randomly assigned, double-blind
Follow-up
1 month
Authors
Loading...
Fasudil may improve endothelial function in CAD; extends Rho kinase inhibition evidence from preclinical models to humans.
Does fasudil improve endothelial function in human subjects with coronary artery disease?
Rho kinase inhibition with fasudil improves endothelium-dependent vasodilation in patients with coronary artery disease, suggesting a potential therapeutic strategy to restore nitric oxide bioavailability.
Nohria et al. (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: